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Abstract  
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme controls 
blood cholesterol levels by down-regulating the expression of the low-density lipoprotein 
receptor (LDLR). Since pathogenic lipids (e.g. LPS) are removed from the bloodstream by an 
LDLR/PCSK9 dependent mechanism, PCSK9 inhibitors have been suggested to be beneficial 
also in the treatment of infections. We quantitated the plasma PCSK9 levels in patients with 
culture-positive bacteremia and explored pathogen and site-of-infection dependent effects as 
well as correlations between patient characteristics and outcome. 
Methods: PCSK9 in the plasma was measured with ELISA from 481 blood culture-positive 
infection patients on days 0 to 4 after admittance to the emergency department. Patient outcome, 
the clinical and laboratory data were gathered retrospectively from patient records. 
Results: The plasma PCSK9 level was elevated equally in patients with Gram-positive or 
Gram-negative bacterial infections; especially high levels were seen in patients with a lower 
respiratory tract infection and Streptococcus pneumoniae bacteremia. PCSK9 levels showed a 
significant positive correlation with CRP. Bacteremia patients with liver disease or a history of 
abusive alcohol use had significantly lower levels of plasma PCSK9. Reduced PCSK9 plasma 
responses in patients were significantly associated with day 7, 28 and 90 mortalities. 
Conclusion: PCSK9 becomes upregulated in blood culture-positive infections. Plasma PCSK9 
resembles acute phase proteins; its expression is induced during an infection, reduced in liver 
disease and correlates positively with CRP. PCSK9 levels were lower in patients with a fatal 
prognosis. 
Key words: PCSK9; sepsis; bacteremia; CRP  
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Introduction 
The proprotein convertase subtilisin/kexin enzyme 9 (PCSK9) is a serine protease that is 
preferentially expressed in the liver and known to possess autoproteolytic activity [1-3]. The 
mature PCSK9 protein serves as a chaperone for cell-surface receptors and escorts them to 
intracellular endosome/lysosome degradation compartments. The key function of PCSK9 is to 
upregulate the levels of circulating low-density lipoprotein (LDL) by reducing the expression 
of the low-density lipoprotein receptor (LDLR) and reducing the clearance of hepatic lipids. 
Patients with a PCSK9 loss-of function genotype are healthy, but show exceptionally low levels 
of LDL and few incidence of coronary heart disease (CHD), which validates PCSK9 as 
biological target for drug development [4]. The first two PCSK9 targeting monoclonal 
antibodies, alirocumab and evolocumab, are now being used to treat patients with statin-
resistant hypercholesterolemia to reduce the risk of cardiovascular events [5, 6]. 
In addition to its fundamental role in cholesterol metabolism PCSK9 also regulates host-defense 
responses. The expression and secretion of PCSK9 are upregulated by inflammatory stimuli via 
the induction of mitochondrial reactive oxygen species (mtROS) and the NF-κB signaling 
pathway [7, 8]. The elevated PCSK9 levels are shown to promote pro-inflammatory and inhibit 
anti-inflammatory cytokines [9]. In septic patients, pathogenic lipids such as lipopolysaccharide 
(LPS, Gram-negative bacteria), lipoteichoic acid (LTA, Gram-positive bacteria), and 
phospholipomannan (PLM, fungal organisms) bind to the host’s pattern-recognition receptors 
(PRRs) and ultimately trigger an uncontrolled systemic inflammatory response. These lipids 
are carried in the circulation within lipoprotein particles and removed through binding to LDLR 
and VLDLR to become detoxified by the liver [10]. In view of this, the upregulation of LDLR 
expression in the liver by inhibiting PCSK9 has recently emerged as a potential strategy to 
reduce exacerbated inflammation in septic patients [11, 12]. According to clinicaltrials.gov, the 
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first clinical phase II/III trials were started in January 2019 (NCT03634293 and 
NCT03869073). 
Boyd and colleagues have investigated the plasma PCSK9 levels in patients that entered the 
emergency department with suspected sepsis [13]. The authors found that PCSK9 was markedly 
increased in the patients compared to reference values from healthy individuals and that there 
was a positive correlation between high PCSK9 levels and cardiovascular and respiratory 
failure. Two other studies have explored the circulating PCSK9 levels in critically ill patients 
that were admitted into intensive care units (ICU) [14, 15]. The results showed that plasma 
concentrations were similarly elevated in septic and non-septic patients and were higher than 
normal in ICU patients with severe trauma injury, which implicates that plasma PCSK9 is also 
upregulated by non-infectious stress to the body. 
In this study, we quantitated the plasma PCSK9 levels during the first four days of 
hospitalization of 481 patients that had blood culture-positive bacteremia when admitted to the 
emergency department (ED). Specifically, we explored the pathogen and site-of-infection 
dependent effects on plasma PCSK9 and its correlation with patient characteristics and 
outcome. Our results demonstrate that a reduced PCSK9 plasma response to an infection is 
significantly associated with a fatal prognosis. 
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Materials and methods 
Bacteremia patient cohort 
Tampere University Hospital is a tertiary hospital with a catchment population of ca. 524 700 
inhabitants in the Pirkanmaa County, Finland. All of the blood culture-positive patients that 
entered the hospital ED between Mar 1, 2012 and Feb 28, 2014 were included in the study 
cohort (contaminants were excluded). The day 0 EDTA blood sample was obtained within 24 
hours after the patient was admitted to the ED. Follow-up plasma samples were collected from 
patients alongside treatment-based routine laboratory testing. Blood cultures were collected in 
BacT/Alert Aerobic (FA Plus) and Anaerobic (FN Plus) blood culture bottles and placed in an 
automated microbial detection system, BacT/Alert 3D (bioMérieux, Marcy l’Etoile, France). 
The clinical data of the patients were collected retrospectively from patient records. Diagnoses 
of severe sepsis and septic shock were made according to Sepsis‐2 consensus definitions [16]. 
A criterion for the qSOFA score was calculated based on Sepsis‐3 definitions [17]. The Pitt 
Bacteremia Score was calculated as presented by Korvick et al [18]. The site of infection was 
determined retrospectively. A more detailed description of the patient cohort is available in our 
previous publications [19, 20]. In addition, we used 17 plasma samples from a separate patient 
cohort as healthy controls. These samples were taken one year after surviving from bacteremia 
[21]. The median PCSK9 level in the control samples was 188 ng/ml (inter-quartile range (IQR) 
139-264), which is in line with the result of a meta-analysis describing the level of PCSK9 in 
healthy individuals [13]. The study was approved by the Ethics Committee of Tampere 
University Hospital, Finland (permit# R11099). The need for informed consent was waived as 
no additional blood sampling was needed and routine patient care was not modified. 
Plasma PCSK9 level measurement 
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Plasma PCSK9 was quantitated from plasma samples using a commercially available ELISA 
assay (R&D Systems, cat#DPC900) and the manufacturer's recommended protocol. To validate 
the reproducibility of the PCSK9 ELISA, some of the samples were measured as duplicates on 
the same or separate plates. The intra-array and between-array variations of the samples were 
on average 3.5% of the defined final concentration.  
Statistical analyses 
SPSS version 22.0 software (IBM Corp., NY, USA) and R (version 3.4.4. https://www.r-
project.org) were used for statistical analyses. Nonparametric data were analyzed using the 
Mann–Whitney U‐test. The Pearson's product-moment coefficient was used to test the 
correlation. A P‐value of <0.05 was considered significant.  
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Results  
PCSK9 levels are equally upregulated in Gram-positive and Gram-negative bacterial 
infections and show a positive correlation with CRP 
During the study period a total of 800 consecutive blood culture-positive cases were admitted 
to the ED [19]. After excluding the contaminants (n=136) and disregarding missed samples due 
to technical reasons we collected the day 0 plasma samples from 481 blood-culture-positive 
cases. As ten patients were admitted twice and one patient three times, the number of individual 
patients in the cohort is 469. Follow-up plasma samples were collected from patients alongside 
treatment-based routine laboratory testing within the first four days of hospitalization. The 
numbers of plasma samples declined during the follow-up because patients were discharged or 
they died, for example. The final numbers of the plasma samples were: day 0: 481, day 1: 446, 
day 2: 389, day 3: 300, day 4: 137.  
The median level of day 0 plasma PCSK9 in patients (376 ng/ml, IQR 293-483) was 
significantly higher than in the control group (188 ng/ml, IQR 139-264, p=0.001). The PCSK9 
level was elevated to the same degree in cases of both a Gram-positive (381 ng/ml, IQR 292-
493 p<0.001) and a Gram-negative (median level 380 ng/ml, IQR 306-465 ng/ml p<0.001) 
bacterial infection, and it remained at equally high levels throughout the sampling period 
(Figure 1). We evaluated the correlation between plasma PCSK9 and infection-associated 
markers. Using Pearson’s product-moment analysis we could not observe a significant 
correlation between PCSK9 plasma levels and body temperature, leukocyte numbers or cell-
free DNA (data not shown). In contrast, there was a significant positive correlation between the 
PCSK9 and CRP levels in plasma samples that were taken during the first 4 days of 
hospitalization (Figure 2 and supplementary Figure 2, day 0: r=0.324, p<0.001, day 1: r=0.270, 
p<0.001, day 2: r=0.251, p<0.001, day 3: r=0.256, p<0.001, day 4: r=0.214, p<0.001).  
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The plasma PCSK9 levels are highest in patients with a lower respiratory tract infection and 
pneumococcal bacteremia 
The plasma PCSK9 levels in relation to different causative organisms are shown in Table 1 
(day 0) and in supplementary Figure 1 (days 1-4). When the microbes or microbe groups with 
a low number of cases (less than 5 samples) were excluded, only patients with a Streptococcus 
pneumoniae –infection showed significantly higher levels of PCSK9 compared to other cases 
on day 0 (476 ng/ml, IQR 319-561, p=0.003). The lowest levels of PCSK9 were seen in patients 
with polymicrobial bacteremia (311 mg/ml IQR 235-501), but this difference was not 
statistically significant. When the patients were grouped based on the site of infection, the 
lowest PCSK9 levels were found in individuals suffering from an unknown or unclassifiable 
infection (Table 2, 352ng/ml, IQR 262-474, p=0.039). Patients with a lower respiratory tract 
infection had especially high plasma PCSK9 levels (472 ng/ml, IQR 315-557, p=0.007), which 
is in accordance with the findings from microbe grouping as Streptococcus pneumoniae is the 
major pneumonia-causing pathogen.  
The association of plasma PCSK9 levels with characteristics of bacteremia patients, underlying 
conditions and severity of the bacteremia 
Table 3 shows the plasma PCSK9 levels on day 0 stratified by various patient characteristics, 
underlying conditions and the severity of the bacteremia. The PCSK9 level was significantly 
lower in males (p=0.001) and in patients with liver disease (p<0.001) or in patients who used 
alcohol abusively (p<0.001). In contrast, there was no significant association between PCSK9 
and age, cardiovascular disease, diabetes, kidney disease, tumors, hematological malignancies 
or use of per oral corticosteroids. On the day of admission, 116 cases (24%) were using statins. 
Simvastatin (63%) and atorvastatin (28%) were the most common with an average dose of 25 
mg and 22 mg, respectively. Patients using statins had significantly higher plasma PCSK9 
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levels (patients not on statins, 363 ng/ml, IQR 283-468, vs. statin users 413 ng/ml, IQR 335-
532, p<0.001).  
In our patient cohort, we found that critically ill patients needing vasopressor treatment had 
significantly lower plasma PCSK9 on day 0 (vasopressor treatment: 316 ng/ml, IQR 256-438 
vs. no vasopressor treatment 379 ng/ml, IQR 298-486, p=0.026). There was also a nearly 
significant trend for lower PCSK9 levels in patients that required ICU care (ICU patients 
343ng/ml, IQR 256-431 vs. others 379ng/ml, IQR 297-486, p=0.050). The severity of 
bacteremia indicators qSOFA score ≥2, Pitt Bacteraemia Score ≥4, severe sepsis (according to 
Sepsis-2 definition) or septic shock (Sepsis-2) were not significantly associated with PCSK9 
levels (p=0.564, p=0.323, p=0.120 and p=0.110, respectively).  
Lower plasma PCSK9 levels in patients with bacteremia are associated with mortality 
In our cohort, the day 7 case fatality rate was 9%. On day 0 the median level of circulating 
PCSK9 was 306 ng/ml (IQR 247-454) in patients who died by day 7 and 381 ng/ml (IQR 298-
486) in patients who survived beyond the first week (p=0.022, Table 4). Patients that 
succumbed by day 28 had also significantly (ca. 20%) lower PCSK9 plasma levels on days 0, 
1, and 2 than survivors. The occurrence of true infection-associated deaths is trumped by 
underlying disease-based mortality when patients are followed beyond the first month from the 
diagnosis of bacteremia. Nevertheless, lower PCSK9 levels on day 0 showed also a significant 
association with the 90-day mortality (death by day 90 320ng/ml, IQR 249-442 vs. survivors 
388ng/ml, IQR 307-489, p=0.001).  
Finally, we evaluated whether the association between PCSK9 levels and death was dependent 
on patient characteristics or underlying conditions that affect PCSK9 levels. In males, low 
PCSK9 levels remained significantly associated with day 7 mortality (p=0.023). The patients 
without statin medication also showed a significant association between their PCSK9 levels on 
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day 0 and lethality (death by day 7: 291 ng/ml IQR 214-438 vs. survivors: 373 ng/ml, IQR 292-
473 ng/ml, p=0.007). Furthermore, there were 49 cases with liver disease that had a high day 7 
and day 28 fatality rate (20% and 31%, respectively) and a low median level of PCSK9 on day 
0 (284 ng/ml, IQR 176-352). In patients with a healthy liver, the association between low 
PCSK9 and death by day 7 or 28 was statistically insignificant (p=0.336 and p=0.059, 
respectively), indicating that the association between PCSK9 and mortality is partly dependent 
on liver disease.  
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Discussion  
To our knowledge, this is the first study that evaluated the level of plasma PCSK9 in blood-
culture positive infections in a large ED patient cohort. Our results demonstrate that plasma 
PCSK9 levels are upregulated in bacteremia patients irrespective of the type of the causative 
organism or infection focus. Especially high PCSK9 levels were seen in patients with a 
Streptococcus pneumonia infection and lower respiratory tract infections. PCSK9 levels show 
a highly significant positive correlation with plasma CRP, and patients with liver disease 
released less PCSK9 into the plasma. Importantly, our findings imply that plasma PCSK9 
resembles the liver-produced acute phase reactants [22], and a lowered PCSK9 response has a 
significant association with a fatal prognosis.  
PCSK9 levels are elevated by an inflammatory response [23] and in critically ill ICU patients 
[14, 15], but how PCSK9 levels behave in different types of bacterial infections has not 
previously been explored. Our bacteremia cases had a median day 0 PCSK9 level of 376 ng/ml, 
which is ca. double of what was reported in a meta-analysis of 15 PCSK9 cholesterol studies, 
wherein the final pooled 95% confidence interval was 170-220 ng/ml [13]. Notably, the patients 
in our small control group, where the bacteremia had been cured, had normal levels of plasma 
PCSK9, which indicates that the elevation of PCSK9 induced by the infection does not persist 
in patients. We could not detect any differences in the levels of plasma PCSK9 between patients 
with Gram-negative or Gram-positive infections. This is in accordance with the findings 
demonstrating that the major lipoproteins of both Gram-negative (LPS) and Gram-positive 
(LTA) bacteria are removed from the circulation in a LDLR/PCSK9 dependent manner [14]. 
Lower respiratory infections, especially those caused by Streptococcus pneumoniae, typically 
result in a severe bodily inflammatory condition as confirmed by a drastic raise in CRP [24]. 
Similarly, high PCSK9 levels in patients with a lower respiratory tract infection and 
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Streptococcus pneumoniae growth in blood culture imply that PCSK9 levels are associated with 
the strength of the inflammatory response. Indeed, when we evaluated the associations between 
infection markers, PCSK9 showed highly significant correlations with CRP levels on days 0-4 
after admission to the ED. This is in line with a previous study where PCSK9 and TNFα plasma 
levels were reported to show a positive correlation in healthy adults [9]. Intriguingly, a recent 
study found that PCSK9 levels were lowered in patients after elective abdominal aortic 
aneurysm repair surgery [25], which indicates that PCSK9 is not universally upregulated upon 
bodily stress. In our study, the majority of patients (445/481) started receiving antibiotic 
treatment on day 0, which could in theory increase the amount of pathogenic lipids in 
circulation. However, we did not observe any significant changes in the PCSK9 levels during 
the first four days hospitalization. 
In addition to inflammatory conditions, plasma PCSK9 levels are elevated by the use of lipid-
lowering drugs, such as statins [26]. We observed a similar upregulation of plasma PCSK9 in 
bacteremia patients using statins, but also identified underlying conditions that were associated 
with lower plasma PCSK9 levels (male sex, liver disease and abusive alcohol use). The PCSK9 
protein is primarily produced by liver cells, and low serum PCSK9 levels negatively correlate 
with poor liver function in non-infectious patients [27]. However, PCSK9 is also expressed in 
other organs, including the brain and small intestine [28, 29]. Our findings showing the 
dependency between liver disease and PCSK9 indicate that in bacteremia patients the main 
source for circulating PCSK9 is the liver, rather than any other organ. 
We found that the reduced elevation of PCSK9 in the plasma of bacteremia patients is 
significantly associated with day 7, 28 and 90 mortalities. Higher circulating PCSK9 levels in 
patients with suspected sepsis have previously been shown to be associated with the 
development of acute organ failure, indicating that higher PCSK9 levels are found in more 
critically ill patients [13]. Our results are conflicting as patients needing mechanical ventilation 
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or vasopressors had significantly lower levels of PCSK9 than those who did not require 
intensive care. Most importantly, patients that were deceased by day 7, 28 or 90 also had 
statistically significantly reduced levels of plasma PCSK9. Notably, the 28 day mortality was 
higher in our cohort than in the previous study by Boyd and colleagues [13] (15% vs. 5%), 
which could reflect the fact that we only included culture-positive cases.  
The exclusion of statin users or restricting the analyses to males did not abolish the association 
between a lowered PCSK9 response and death. In contrast, the lethality was at least partly 
dependent on the liver disease as well as affiliated abusive alcohol usage. This is in line with 
the previous findings with non-infectious patients with end-stage liver disease [27]. Schengel 
and colleagues found that liver patients had lower serum PCSK9 levels (medium 106.39ng/ml) 
than healthy populations, and that there was a negative correlation between serum PCSK9 and 
markers of liver function. In our bacteremia cohort, PCSK9 levels are upregulated by infection 
also in patients with liver disease, but by a lesser magnitude. It is thus important to note that 
even higher-than-normal plasma PCSK9 levels can be associated with lethality in bacteremia 
patients. 
PCSK9 blocking antibodies have been proposed to be beneficial in reducing the lipoprotein-
triggered inflammation in patients with a systemic infectious disease [11, 12]. Our results show 
that higher plasma PCSK9 levels are not detrimental to bacteremia patients. It is also important 
to note that in an experimental model the inhibition of PCSK9 was not found to improve 
lipopolysaccharide-induced mortality in mice [30], and that a slight rise in the incidence of 
upper respiratory tract infections was observed in patients using PCSK9 inhibitors (2.1% 
alirocumab vs. 1.1% placebo) [31, 32]. Moreover, a recent study showed that a PCSK9 loss-of-
function variant was not associated with an increased risk of hospitalization for a serious 
infection [33]. Hence, the use of PCSK9 inhibitors in sepsis remains controversial. 
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Our study has some limitations that need to be addressed. This was a single-centered tertiary 
hospital study involving only culture-positive patients. Our results should not be extrapolated 
to culture-negative cases with an infection and should be reproduced using an independent 
study cohort. A few cases of culture-positive result were missed due to technical problems in 
sample collection/storage, but the number of these samples is low and the possible bias has 
been analyzed to be insignificant [19]. 
In conclusion, PCSK9 remains in the limelight when novel diagnostic and treatment options for 
systemic infectious diseases are considered. As the PCSK9 inhibitors have only recently been 
added to the clinical toolbox, our understanding of their effects in the course of severe infections 
is still sparse. As data from the PCSK9 plasma level measurements accumulate, we will begin 
to better understand PCSK9s significance in health and disease. 
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Table 1. Causative organisms and the median level of PCSK9 on the day of admission to the 
emergency department. 
Organisms n (%) Median plasma PCSK9 
level (ng/ml) with inter-
quartile range 
Gram-positive  213 (44) 381 (292-493)1 
 Staphylococcus aureus 71 (15) 358 (293-479) 
 Coagulase-negative Staph. 11 (2) 421 (278-484) 
 Streptococcus pneumoniae 46 (10) 476 (319-561) 
 β-hemolytic streptococci 43 (9) 382 (288-498) 
 Viridans streptococci 21 (4) 353 (287-470) 
 Enterococci 17 (4) 333 (267-414) 
 Other Gram-positive 4 (1) 618 (327-958) 
Gram-negative  222 (46) 380 (306-465)2 
 E. coli 156 (32) 388 (306-442) 
 Klebsiella sp. 23 (5) 392 (340-520) 
 Pseudomonas aeruginosa 18 (4) 345 (292-416) 
 Other Gram-negative 25 (5) 315 (226-494) 
Others 46 (10) 339 (261-488)3 
 Anaerobes 15 (3) 374 (318-464) 
 Fungi 1 (0.2) 275 (275-275) 
 Polymicrobial 30 (6) 311 (235-501) 
All 481 (100) 376 (293-483) 
 
  
                                                            
1 Day 7 case fatality rate 5.6% 
2 Day 7 case fatality rate 9.5% 
3 Day 7 case fatality rate 23.9% 
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Table 2. Site of infection, number of deceased patients by day 7 and the median level of PCSK9 
(ng/ml) on the day of admission to the emergency department. There were 29 cases with two 
different infection sites. 
Site of infection n (%) Deceased n (%) Median plasma PCSK9 level 
(ng/ml) with inter-quartile range 
Unknown/unclassifiable 116 (24) 18 (16) 352 (262-474) 
Urinary tract infection 134 (28) 9 (7) 388 (303-468) 
Intra-abdominal 83 (17) 12 (15) 365 (291-443) 
Skin, soft tissue and bones 65 (14) 2 (3) 377 (306-527) 
Lower respiratory tract 48 (10) 4 (8) 472 (315-557) 
Surgical site or foreign body 36 (7) 0 (0) 367 (287-474) 
Others 19 (4) 1 (5) 374 (310-447) 
  
 20 
Table 3. Plasma PCSK9 levels on the day of admission to the emergency department stratified 
by various characteristics, underlying conditions and the severity of the bacteremia. 
  Plasma PCSK9 level(ng/ml) on day of admission  
  factor present, 
median (quartiles) 
factor absent, 
median (quartiles) 
p-value 
Characteristics and underlying 
conditions 
n (%)    
Male 253 (53) 356 (273-472) 405 (310-492) 0.001 
Age over 60 years 333 (69) 381 (298-486) 368 (275-478) 0.223 
Age over 80 years 107 (22) 379 (304-477) 376 (289-485) 0.804 
Cardiovascular disease 155 (32) 388 (299-479) 371 (291-484) 0.868 
Diabetes any type 137 (29) 375 (295-468) 379 (292-487) 0.591 
Chronic kidney disease4 66 (14) 364 (297-440) 379 (292-487) 0.152 
Liver disease 49 (10) 284 (176-352) 389 (305-488) <0.001 
Alcohol abuse5 49 (10) 264 (190-388) 388 (306-489) <0.001 
Solid tumour with metastasis 55 (11) 399 (291-484) 375 (293-482) 0.783 
Haematological malignancy 45 (9) 382 (308-485) 376 (291-484) 0.508 
Use of oral corticosteroids 92 (19) 415 (306-487) 370 (291-480) 0.125 
Use of statins 116 (24) 413 (335-532) 363 (283-468) <0.001 
Severity of bacteremia n (%)    
qSOFA score ≥26 128 (28) 378 (263-489) 376 (299-480) 0.564 
Need of vasopressor 49 (10) 316 (256-438) 379 (298-486) 0.026 
Need of mechanical ventilation 24 (5) 309 (235-593) 377 (395-481) 0.631 
Severe sepsis7 145 (30) 363 (266-477) 380 (301-486) 0.120 
Septic shock4 36 (8) 347 (256-438) 378 (296-486) 0.110 
Admitted from ED to ICU 44 (9) 343 (256-431) 379 (297-486) 0.050 
                                                            
4 History of creatinine more than 120 µmol/l 
5 Social or medical problems of alcohol abuse in the past 12 months 
6 Data available on 458 cases 
7 According to Sepsis-2 definition 
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Pitt Bacteraemia Score ≥48 58 (12) 344 (262-493) 380 (298-482) 0.323 
Death by day 7 45 (9) 306 (257-454) 381 (298-486) 0.022 
Death by day 28 71 (15) 308 (242-431) 387 (299-487) 0.001 
Death by day 90 101 (21) 320 (249-441) 388 (307-489) 0.001 
 
                                                            
8 Data available on 474 cases 
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Table 4. Plasma PCSK9 levels during days 0 to 4 after admission to the emergency department in all cases and in deceased individuals and 
survivors by days 7 and 28. 
Days after 
admission 
Plasma PCSK9 (ng/ml), median (quartiles)    
 All Deceased by day 7 Survivors by day 7 p-value Deceased by day 28 Survivors by day 28 p-value 
Day 0 376 (293-483) 306 (247-454) 381 (298-486) 0.022 308 (242-431) 387 (299-487) 0.001 
Day 1 383 (296-484) 351 (228-435) 385 (300-485) 0.062 348 (213-429) 389 (303-488) 0.003 
Day 2 381 (295-478) 321 (248-429) 385 (298-482) 0.030 330 (219-446) 387 (300-490) 0.005 
Day 3 360 (283-465) 348 (225-428) 364 (284-472) 0.216 355 (268-438) 360 (284-470) 0.717 
Day 4 356 (274-452) 324 (189-440) 359 (274-457) 0.557 344 (242-444) 356 (275-460) 0.646 
Maximum level 
day 0-4 
455 (362-566) 360 (256-502) 457 (374-559) <0.001 378 (256-506) 470 (376-560) <0.001 
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Figure 1. PCSK9 plasma levels of bacteremia patients 
PCSK9 concentration of 481 bacteremia patients and 17 controls were measured using ELISA. 
Box plot representation of the PCSK9 plasma levels in patients with a Gram-positive or Gram-
negative infection and in controls on days 0 – 4 are shown. The box represents the interquartile 
range (25th–75th percentiles) and the whiskers represent the 10th–90th percentiles. Dashed lines 
mark the reported normal plasma PCSK9 range (170-220ng/ml) [13]. PCSK9 levels of Gram-
positive and Gram-negative groups were compared to a control group (ctrl) and both were 
significantly elevated (*** p<0.001, Welch’s two sample t tests). 
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Figure 2. Correlation between plasma PCSK9 and CRP levels in bacteremia patients 
PCSK9 and CRP levels were measured from bacteremia patients on the day of admission to the 
emergency department. Plasma PCSK9 levels are plotted against CRP and the correlation was 
studied by calculating the Pearson’s product-moment correlation coefficient (r). The shadowed 
area shows the 95% confidence interval. 
